Category: Epidarex Portfolio News
Aberdeen, United Kingdom, January 10, 2017 – SIRAKOSS Ltd., a UK-based medical device company developing innovative bone grafting solutions for the $3 billion global orthopaedic market, has announced that the United States Patent and Trademark Office (USPTO) has granted two patents for its bone graft…
Berlin, Germany, 09 January 2017 – Eternygen GmbH, a privately owned Berlin-based metabolic diseases company, today announced the completion of its € 8.0 (approx. US$ 8.3) million Series A funding round. Epidarex Capital led the round, and Evotec AG participated together with a consortium of investors…
Mironid’s ShoLo® and LoAc® programmes benefit from a close association with Dr George Muller as a key medicinal chemistry and experienced drug development advisor. George was an Outstanding Investigator and Senior Director of Chemistry with Celgene until his retirement in mid-2011. George has a deep…
C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience hemolysis and require RBC transfusions despite receiving treatment with eculizumab Louisville, Ky., December 20, 2016 – Apellis Pharmaceuticals, Inc., a…
Glasgow, Scotland, and Sheffield, UK, 12th December 2016 – Mironid Ltd, a leader in cell signalling-directed drug development, and the University of Sheffield, announced today that they have signed a collaboration agreement to identify and develop new molecules for the treatment of Autosomal Dominant Polycystic…
Mironid is delighted to announce that Prof Albert Ong DM MA FRCP, Professor of Renal Medicine, Department of Infection Immunity & Cardiovascular Disease, University of Sheffield has joined our Scientific Advisory Board. Albert brings enormous experience of the molecular, cellular and clinical aspects of Autosomal…
Louisville, Ky., December 2, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim results from two ongoing Phase Ib open-label, dose-escalation clinical trials of APL-2, a complement C3 inhibitor, in paroxysmal nocturnal hemoglobinuria…
Brighton, UK, November 10, 2016: Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has closed a £4 million ($5 million USD) financing. The funding was led by…